Table 2: Baseline characteristics of patients with seasonal influenza A and pandemic H1N1 with relevant positive bacteriological cultures. Number (% of the total).

Influenza AH1N1Statistical analysis

Influenza patients with bacteriological relevant findings3338
Age—median (min-max) 57.5 (38–74)30.5 (17–43)
Female gender/total (%)19/33 (57.58%)25/38 (65.79%)NS
Diabetes mellitus2/33 (6.06%)0NS
Chronic lung disease*5/33 (15.15%)8/38 (21.05%)NS
Chronic cardiovascular disease7/33 (21.21%)1/38 (2.63%)
Immunosuppression**12/33 (36.36%)11/38 (28.95%)NS
Chronic renal disease 3/33 (9.09%)4/38 (10.53%)NS
Total number of patients with comorbidity26/33 (78.79%)19/38 (50.0%)
Time between first symptoms to hospital admission (days)34ND
Hospital admission30/33 (90.90%)24/38 (63.16%)
ICU admission2/33 (6.06%)11/38 (28.95%)
Length of hospital stay including ICU (days)8.513.5
Antimicrobial treatment
Antiviral treatment10/30 (30.30%)18/38 (47.37%)NS
Antibacterial treatment26/33 (78.79%)25/38 (65.79%)NS
Overall mortality 12/33 (36.36%)3/38 (7.89%)
Mortality within 4 weeks of influenza diagnosis2/33 (6.06%)1/38 (2.63%)NS
Mortality due to influenza complications 4/33 (12.12%)3/38 (7.89%)NS

ND: not determined; NS: not significant; *asthma or COPD, cystic fibrosis; **kidney/liver transplantation, solid tumor, chemotherapy, acute myelogenous leukaemia (AML), chronic myelogenous leukaemia (CML), autologous stem cell transplant (ASCT), and chronic lymphocytic leukaemia (CLL).